"Discussions with the FDA indicated that the supporting data did not meet the requirements for accelerated approval, leading Merck and Daiichi Sankyo to voluntarily withdraw their application for ifinatamab deruxtecan (I-DXd) in previously treated extensive-stage small cell lung cancer."
This decision significantly impacts the near-term treatment landscape for a highly aggressive cancer, closing off a potentially faster route to a new therapy for patients who have exhausted standard platinum chemotherapy. While the specific concerns raised by the U.S. Food and Drug Administration (FDA) remain undisclosed, the withdrawal signifies a critical hurdle in the drug’s path to market, underscoring the rigorous data standards required for accelerated pathways.
Merck and Daiichi Sankyo have made the strategic decision to withdraw their Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) seeking accelerated approval from the U.S. Food and Drug Administration (FDA) for adults with extensive-stage small cell lung cancer (SCLC) whose disease has progressed following platinum-based chemotherapy. The companies announced on September 25th that ongoing dialogue with the FDA revealed that the submitted data, including findings from the pivotal Phase 2 IDeate-Lung01 trial, did not sufficiently meet the criteria for accelerated approval.
While the FDA has not publicly detailed its reasoning for this assessment, and the pharmaceutical partners have refrained from elaborating on the agency’s specific concerns, the application had previously received a priority review designation in April. This withdrawal represents a significant setback for patients and their families, particularly given the limited therapeutic options available for extensive-stage SCLC after initial chemotherapy. According to Merck, approximately 27,000 individuals in the United States are diagnosed with SCLC annually, a cancer characterized by its rapid progression and challenging treatment resistance.
Understanding Accelerated Approval and its Implications
The FDA’s accelerated approval pathway is designed to expedite access to innovative treatments for serious or life-threatening conditions. This regulatory mechanism allows for the approval of a drug based on surrogate endpoints, such as a significant reduction in tumor size (objective response rate), that are reasonably likely to predict a clinical benefit, such as improved survival. The fundamental premise is that this early evidence provides a strong signal of potential efficacy, allowing patients to benefit from a new therapy sooner. However, this expedited pathway comes with a critical caveat: companies are required to conduct post-marketing confirmatory trials to verify the predicted clinical benefit. The FDA’s decision to not grant accelerated approval for I-DXd suggests that the submitted data, while showing some promise, did not provide a sufficiently robust signal to satisfy the agency’s confidence in its predictive value for a meaningful clinical outcome.
Analysis of the IDeate-Lung01 Phase 2 Trial Data
The primary analysis of the Phase 2 IDeate-Lung01 trial, published in the Journal of Clinical Oncology, evaluated two doses of I-DXd. For patients receiving the 12 mg/kg dose, the study reported a confirmed objective response rate (ORR) of 48.2%, indicating that nearly half of the participants experienced a significant shrinkage of their tumors. The median duration of response was 5.3 months, with a median progression-free survival (PFS) of 4.9 months, meaning the time from treatment initiation until disease worsening or death was nearly five months. Furthermore, an estimated 59.1% of patients were alive at the nine-month mark.
While these response rates are noteworthy, a critical limitation of the IDeate-Lung01 trial, and likely a contributing factor to the FDA’s decision, is its design. The trial primarily compared two different doses of I-DXd against each other, rather than directly comparing the drug to an existing standard of care in a head-to-head manner. This absence of a concurrent control arm makes it more challenging to definitively attribute the observed outcomes solely to the efficacy of I-DXd. Without a comparator group receiving a different treatment or placebo, it becomes more difficult for regulatory bodies to ascertain the true magnitude of benefit, particularly concerning overall survival, which is a more definitive measure of clinical benefit.
Safety Profile and Patient Considerations
Beyond efficacy signals, the safety profile of I-DXd in the Phase 2 trial also warrants careful consideration. In patients receiving the 12 mg/kg dose, a substantial 62% experienced Grade 3 or higher adverse events, signifying serious toxicities. Furthermore, 39.4% of patients reported serious adverse events, highlighting the drug’s potential for significant toxicity. Notably, adverse events associated with death were reported in 11.7% of patients, though it is important to note that this figure includes all reported deaths, not necessarily those directly attributable to the drug. To mitigate risks associated with lung toxicity, patients with a history of lung inflammation requiring steroid treatment were excluded from the trial, underscoring a specific safety concern.
Dr. Marjorie Green, Senior Vice President and Head of Oncology, Global Clinical Development at Merck Research Laboratories, expressed disappointment but emphasized the ongoing commitment to evaluating I-DXd: "While we are disappointed that the current dataset are not supportive of an approval at this time, we are continuing to evaluate the role of ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer and other types of difficult-to-treat cancer."
The Crucial Role of Phase 3 IDeate-Lung02 Trial
The responsibility of demonstrating the definitive clinical benefit of I-DXd now rests heavily on the ongoing Phase 3 IDeate-Lung02 trial. This large-scale study is designed as a randomized, controlled trial, directly comparing I-DXd against a physician’s choice of chemotherapy, which includes amrubicin, lurbinectedin, or topotecan, in patients whose SCLC has recurred after one prior platinum-based treatment. The primary endpoint of the IDeate-Lung02 trial is overall survival (OS), the gold standard measure for determining whether a treatment prolongs life.
The Phase 3 trial aims to enroll approximately 540 patients, with primary completion anticipated in January 2028, according to reports from OncLive. Dr. Abderrahmane Laadem, Head of Therapeutic Area Oncology Development at Daiichi Sankyo, indicated that patient enrollment is nearing completion. The companies plan to reassess a potential future FDA filing based on the comprehensive results from this pivotal Phase 3 study.
Strategic Partnership and Broader Pipeline Implications
The withdrawal also casts a shadow over the significant strategic partnership between Merck and Daiichi Sankyo. In 2023, Merck invested $4 billion upfront for the rights to three of Daiichi Sankyo’s antibody-drug conjugate (ADC) candidates, including I-DXd. This collaboration aimed to bolster Merck’s oncology pipeline with innovative ADC technology. The setbacks encountered by I-DXd, coupled with a prior FDA rejection letter in 2024 for patritumab deruxtecan (another candidate from the same deal) due to manufacturing inspection issues, suggest ongoing challenges in navigating the regulatory landscape for these novel agents. Patritumab deruxtecan’s application was subsequently withdrawn in 2025. I-DXd is also under investigation in Phase 3 trials for prostate and esophageal cancers, highlighting its broader potential across various malignancies.
Current Treatment Options for Relapsed Small Cell Lung Cancer
Despite the delay in I-DXd’s potential approval, patients with relapsed SCLC are not without treatment options. Amgen’s Imdelltra (tarlatamab-dlle), a T-cell engaging bispecific antibody, has received FDA approval for adult patients with extensive-stage SCLC whose disease has progressed on or after platinum-based chemotherapy. Additionally, established chemotherapy agents such as topotecan and lurbinectedin remain important treatment modalities. The selection of the most appropriate therapy depends on individual patient factors, including the speed of cancer recurrence, overall health status, and previous treatment regimens.
The Evolving Landscape of SCLC Treatment
The field of SCLC treatment remains dynamic, with ongoing research and development efforts to address unmet needs. Fierce Biotech has reported that GSK is developing a rival drug targeting the same B7-H3 receptor, indicating competitive interest in this therapeutic pathway. The continuous exploration of new agents, even those facing regulatory hurdles, can create more opportunities for patients to enroll in clinical trials, offering access to investigational therapies.
Small cell lung cancer is intrinsically linked to smoking, and a significant proportion of patients are older adults who may have co-existing cardiac or pulmonary conditions. These comorbidities can influence treatment tolerance and the types of therapies that can be safely administered. Therefore, comprehensive discussions between patients and their oncologists regarding potential side effects, quality of life implications, and the risks and benefits of available treatments are paramount.
Navigating Clinical Trials and Access Programs
For patients who were anticipating I-DXd as a treatment option, exploring clinical trials remains a viable avenue. ClinicalTrials.gov is a valuable resource for identifying ongoing studies. Furthermore, Daiichi Sankyo operates a medical access program for I-DXd, offering the investigational drug to heavily pretreated patients at select institutions, including UT Southwestern Medical Center in Dallas, Duke Cancer Institute, and HealthPartners in Minnesota. Availability and eligibility criteria for these programs can fluctuate, and it is essential for patients and their families to confirm the current status with their healthcare team.
Caregivers play a crucial role in supporting patients through this complex journey. Preparing for discussions with oncologists by gathering essential medical information, such as pathology reports, treatment timelines, and recent imaging results, can facilitate more informed decision-making. Prompt reporting of any new symptoms, such as increased shortness of breath, persistent cough, or fever, is critical, and severe respiratory distress or chest pain requires immediate emergency medical attention.
Financial considerations can also significantly influence treatment choices. Patients and their families should engage with the oncology team’s financial counselors to understand insurance coverage for clinical trials and to inquire about manufacturer assistance programs for approved therapies.
It is crucial for patients to understand that I-DXd is not currently an approved treatment, and full survival data from the Phase 3 trial are not expected for several years. Treatment decisions should be made in consultation with the oncology team, based on currently available approved therapies and investigational options, rather than waiting for a future regulatory submission.
Key Questions Answered
What happened?
Merck and Daiichi Sankyo voluntarily withdrew their application for accelerated FDA approval of ifinatamab deruxtecan (I-DXd) for previously treated extensive-stage small cell lung cancer following discussions with the FDA.
Did the FDA explain why?
Publicly, the FDA has not detailed its specific reasons. The companies stated that discussions with the agency indicated the submitted data did not meet the requirements for accelerated approval.
Can patients still get I-DXd?
Potentially, yes. Patients may be eligible for I-DXd through ongoing clinical trials or a listed medical access program. It is essential to consult with an oncologist to discuss eligibility and current availability.
What treatments are approved now?
Currently approved options for relapsed extensive-stage small cell lung cancer include Amgen’s Imdelltra (tarlatamab-dlle) and chemotherapy drugs such as topotecan and lurbinectedin. The best choice depends on individual patient circumstances.
When could the drug return to the FDA?
A potential refiling with the FDA could occur after the completion and analysis of the Phase 3 IDeate-Lung02 trial results. Primary completion for this trial is anticipated in January 2028.
What side effects were seen in the Phase 2 trial?
In the Phase 2 IDeate-Lung01 trial, 62% of patients on the higher dose (12 mg/kg) experienced Grade 3 or higher adverse events. Patients with a history of lung inflammation requiring steroid treatment were excluded from this trial.
